# MAGEA3

## Overview
MAGEA3 is a gene that encodes the protein MAGE family member A3, which belongs to the melanoma antigen gene (MAGE) family. This family is characterized by its involvement in various cellular processes, including protein-protein interactions and ubiquitination. MAGEA3 is primarily expressed in male germ cells and certain tumors, where it plays a significant role in spermatogenesis and tumor progression. The protein is known for its interaction with E3 ubiquitin ligases, such as TRIM28, which facilitates the degradation of tumor suppressors, thereby contributing to oncogenesis. MAGEA3's expression is often upregulated in several cancers, including hepatocellular carcinoma and pancreatic ductal adenocarcinoma, where it is associated with poor prognosis and tumor aggressiveness. Due to its role in cancer progression and its potential as a therapeutic target, MAGEA3 is a subject of interest in cancer research (Craig2021Transcriptomic; Schäfer2021Oncogenic; Lee2017A).

## Structure
The MAGEA3 protein, a member of the MAGE family, is primarily expressed in tumors and certain normal tissues. Its primary structure consists of a sequence of amino acids encoded by the MAGEA3 gene. The protein is known to contain specific domains, such as the MAGE homology domain, which is characteristic of the MAGE family proteins. This domain is involved in protein-protein interactions and may play a role in the regulation of cellular processes (Craig2021Transcriptomic).

The secondary structure of MAGEA3 includes common elements such as alpha helices and beta sheets, which contribute to its overall stability and function. The tertiary structure refers to the three-dimensional conformation of the protein, which is crucial for its interaction with other molecules, such as the E3 ubiquitin ligase TRIM28, leading to the degradation of tumor suppressors like TP53 and AMPK (Craig2021Transcriptomic).

MAGEA3 can undergo post-translational modifications, such as phosphorylation, which may affect its activity and interactions. The protein also has splice variant isoforms, resulting in different versions with distinct functions, potentially contributing to its role in tumor progression and apoptosis evasion (Craig2021Transcriptomic).

## Function
MAGEA3 is primarily expressed in male germ cells, particularly in the testis, where it plays a significant role in spermatogenesis. It is expressed in migrating primordial germ cells and in the nuclei and cytoplasm of spermatogonia and primary spermatocytes, but not in spermatids or Sertoli cells. This expression pattern suggests an active role in the early stages of germ cell development (Lee2017A). Mouse models with deletions of several Mage-a genes, including MAGE-A3, exhibit reduced testis size and increased apoptosis in germ cells, indicating its critical role in germ cell development (Lee2017A).

MAGEA3 is part of the MAGE-RING ligases (MRLs) complex, interacting with E3 RING ubiquitin ligases. These complexes are involved in various cellular processes by enhancing ligase activity, specifying novel substrates for ubiquitination, and altering subcellular location. Ubiquitination, facilitated by E3 ligases, regulates many cellular functions, including proteasomal degradation, endocytosis, DNA repair, and activation of kinases and transcription factors (Lee2017A). MAGEA3's involvement in these processes suggests it may undergo conformational changes to interact with distinct protein domains, conferring unique functions to individual MAGE proteins (Lee2017A).

## Clinical Significance
The MAGEA3 gene is clinically significant due to its role in various cancers, where it is often overexpressed and contributes to tumor progression and poor prognosis. In hepatocellular carcinoma (HCC), MAGEA3 acts as a driver of tumor progression by inhibiting apoptosis through the stabilization of Survivin, an anti-apoptotic protein. Its expression is associated with poor clinical outcomes, including metastasis and tumor recurrence (Craig2021Transcriptomic). In pancreatic ductal adenocarcinoma (PDAC), MAGEA3 expression correlates with decreased overall survival, making it a significant prognostic factor (Kim2005The). 

In multiple myeloma, MAGEA3 expression is higher in relapsed patients, suggesting a role in disease progression by inhibiting apoptosis through repression of the pro-apoptotic Bax gene and maintenance of Survivin expression (Nardiello2011MAGEA). MAGEA3 also affects the regulation of p53 activity, contributing to cancer cell survival by promoting the degradation of this tumor suppressor protein (Schäfer2021Oncogenic). 

The gene's oncogenic potential is further highlighted by its involvement in transcriptional regulation and interaction with E3 RING ubiquitin ligases, enhancing tumorigenesis by affecting protein ubiquitination and degradation (Poojary2020Prognostic). These interactions make MAGEA3 a potential target for therapeutic interventions in cancer.

## Interactions
MAGEA3, a member of the melanoma antigen family, is involved in various protein interactions that influence its function and stability. It interacts with several proteins, including MAGEA12, PRAME, and CSAG1, as identified through protein-protein interaction (PPI) network analysis. These interactions are positively correlated with MAGEA3 expression in gastric cancer (Jin2021Comprehensive).

MAGEA3 also interacts with the DCAF12 protein, a component of the CRL4 E3 ubiquitin ligase complex. This interaction is crucial for the degradation of MAGEA3, mediated by its C-terminal degrons characterized by double-glutamic acid residues. The binding involves specific arginine residues in the DCAF12 WDR domain, such as Arg203, Arg256, and Arg344, which are essential for the interaction. Mutations in these residues significantly impair the binding, highlighting their importance (Righetto2023Probing; Righetto2024Probing).

The structural basis of the MAGEA3-DCAF12 interaction has been elucidated using cryo-EM, revealing that the C-terminal -EE degron of MAGEA3 binds to the central channel of DCAF12. This interaction is facilitated by positively charged residues in DCAF12, which enhance substrate binding (Righetto2023Probing; Righetto2024Probing).


## References


1. (Righetto2023Probing) Probing the DCAF12 interactions with MAGEA3 and CCT5 C-terminal degrons. This article has 0 citations.

[2. (Schäfer2021Oncogenic) Paula Schäfer, Themistoklis Paraschiakos, and Sabine Windhorst. Oncogenic activity and cellular functionality of melanoma associated antigen a3. Biochemical Pharmacology, 192:114700, October 2021. URL: http://dx.doi.org/10.1016/j.bcp.2021.114700, doi:10.1016/j.bcp.2021.114700. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2021.114700)

[3. (Jin2021Comprehensive) Jinji Jin, Jianxin Tu, Jiahuan Ren, Yiqi Cai, Wenjing Chen, Lifang Zhang, Qiyu Zhang, and Guanbao Zhu. Comprehensive analysis to identify magea3 expression correlated with immune infiltrates and lymph node metastasis in gastric cancer. Frontiers in Oncology, December 2021. URL: http://dx.doi.org/10.3389/fonc.2021.784925, doi:10.3389/fonc.2021.784925. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.784925)

[4. (Kim2005The) Joseph Kim, Howard A. Reber, Oscar J. Hines, Kevork K. Kazanjian, Andy Tran, Xing Ye, Farin F. Amersi, Steve R. Martinez, Sarah M. Dry, Anton J. Bilchik, and Dave S.B. Hoon. The clinical significance of magea3 expression in pancreatic cancer. International Journal of Cancer, 118(9):2269–2275, December 2005. URL: http://dx.doi.org/10.1002/ijc.21656, doi:10.1002/ijc.21656. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.21656)

[5. (Craig2021Transcriptomic) Amanda J. Craig, Teresa Garcia-Lezana, Marina Ruiz de Galarreta, Carlos Villacorta-Martin, Edgar G. Kozlova, Sebastiao N. Martins-Filho, Johann von Felden, Mehmet Eren Ahsen, Erin Bresnahan, Gabriela Hernandez-Meza, Ismail Labgaa, Delia D’Avola, Myron Schwartz, Josep M. Llovet, Daniela Sia, Swan Thung, Bojan Losic, Amaia Lujambio, and Augusto Villanueva. Transcriptomic characterization of cancer-testis antigens identifies magea3 as a driver of tumor progression in hepatocellular carcinoma. PLOS Genetics, 17(6):e1009589, June 2021. URL: http://dx.doi.org/10.1371/journal.pgen.1009589, doi:10.1371/journal.pgen.1009589. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1009589)

[6. (Righetto2024Probing) Germanna Lima Righetto, Yanting Yin, David M Duda, Victoria Vu, Magdalena M Szewczyk, Hong Zeng, Yanjun Li, Peter Loppnau, Tony Mei, Yen-Yen Li, Alma Seitova, Aaron N Patrick, Jean-Francois Brazeau, Charu Chaudhry, Dalia Barsyte-Lovejoy, Vijayaratnam Santhakumar, and Levon Halabelian. Probing the crl4dcaf12 interactions with magea3 and cct5 di-glu c-terminal degrons. PNAS Nexus, March 2024. URL: http://dx.doi.org/10.1093/pnasnexus/pgae153, doi:10.1093/pnasnexus/pgae153. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/pnasnexus/pgae153)

[7. (Lee2017A) Anna K. Lee and Patrick Ryan Potts. A comprehensive guide to the mage family of ubiquitin ligases. Journal of Molecular Biology, 429(8):1114–1142, April 2017. URL: http://dx.doi.org/10.1016/j.jmb.2017.03.005, doi:10.1016/j.jmb.2017.03.005. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2017.03.005)

[8. (Poojary2020Prognostic) Manish Poojary, Padacherri Vethil Jishnu, and Shama Prasada Kabekkodu. Prognostic value of melanoma-associated antigen-a (mage-a) gene expression in various human cancers: a systematic review and meta-analysis of 7428 patients and 44 studies. Molecular Diagnosis &amp; Therapy, 24(5):537–555, June 2020. URL: http://dx.doi.org/10.1007/s40291-020-00476-5, doi:10.1007/s40291-020-00476-5. This article has 20 citations.](https://doi.org/10.1007/s40291-020-00476-5)

[9. (Nardiello2011MAGEA) Tricia Nardiello, Achim A. Jungbluth, Anna Mei, Maurizio DiLiberto, Xiangao Huang, Ania Dabrowski, Valéria C.C. Andrade, Rebecca Wasserstrum, Scott Ely, Ruben Niesvizky, Roger Pearse, Morton Coleman, David S. Jayabalan, Nina Bhardwaj, Lloyd J. Old, Selina Chen-Kiang, and Hearn Jay Cho. Mage-a inhibits apoptosis in proliferating myeloma cells through repression of bax and maintenance of survivin. Clinical Cancer Research, 17(13):4309–4319, July 2011. URL: http://dx.doi.org/10.1158/1078-0432.ccr-10-1820, doi:10.1158/1078-0432.ccr-10-1820. This article has 73 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-10-1820)